Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis. - Wikidata - awgldk - TriplyDB

Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.

Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.

http://www.wikidata.org/entity/Q33415971

about

A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.

P2860

Q35612770-EF966E5C-8485-41CC-96D9-3C2B204A8F26 Q39728271-A2D086FB-82E7-4F6A-9E7B-BDAC23603E6D

P2860

Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.

http://www.wikidata.org/entity/Q33415971

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@ast

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@en

type

label

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@ast

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@en

prefLabel

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@ast

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@en

P1433

Q33415971-33664CC0-3813-4470-A7CE-37DE3A92AD42

P1476

Q33415971-2A670303-4547-4D73-9A45-0ECBACF568F2

P2093

Q33415971-2FDAF633-7567-490C-B888-A87FF9DD565B

Q33415971-314A18DA-7E21-4428-9D8B-AC1A125B9264

Q33415971-7CC41062-77A0-4D8F-99B5-235A9F045AB6

Q33415971-99C5B2A9-8503-4A72-A707-C605D0449F32

Q33415971-AB1A267F-4336-4216-98C1-E0318D53B83D

P2860

Q33415971-155E3005-DA34-467C-BB2C-B8090D092C88

Q33415971-33EE1013-E35E-43CA-BC51-7A7F0606C0F2

Q33415971-408B0D6D-FAF8-45FA-AD5E-5DBFCFF8DAF7

Q33415971-542FFD38-33F4-4625-B3D1-3F9890DF179F

Q33415971-58896F8A-BA74-40FB-BCF1-031DD33E7651

Q33415971-626A7AE6-071F-48AE-BEAE-089EA23C5AE6

Q33415971-6B24DC9A-EACD-4D90-B528-BB8E79FF9C7A

Q33415971-70594357-5630-4176-B5DA-7996CC72F512

Q33415971-87BF9383-04D5-4F73-940D-A745AF1402F8

Q33415971-A4876A25-1409-4307-A4CF-23DC96A1DD05

P304

Q33415971-16D48E05-7A61-42FF-A873-11011479D030

P31

Q33415971-14D781A9-AB98-44B5-B69E-E6B18AB5E533

P356

Q33415971-934FBC02-A865-4ABE-AF54-ADAFC550F75F

P433

Q33415971-1420BBE7-FF43-4A57-B6DC-687ED95E4530

P478

Q33415971-C8E05497-863F-41BE-AC5A-28B267A2A5DB

P577

Q33415971-61DFB0D8-9AB3-4673-83F7-27D5C4E94442

P5875

Q33415971-5C0EB2D9-1DA2-4D89-B637-9019176B7150

P698

Q33415971-26E4B892-86C6-4891-BACD-4A8D2723A31C

P921

Q33415971-1F1491BE-5932-4CFF-B735-50FDE71CCFE2

Q33415971-ADC6D7CF-A5ED-404B-AC8C-D2677089B188

P932

Q33415971-151B1041-453F-4345-BE1B-31F3FADA57FA

P356

P1433

Experimental and Therapeutic Medicine

P1476

Effectiveness and safety profi ...... ectal cancer: A meta-analysis.

@en

P2093

Ai-Qun Liu

http://www.w3.org/2001/XMLSchema#string

Jia-Xiang Ye

http://www.w3.org/2001/XMLSchema#string

Lian-Ying Ge

http://www.w3.org/2001/XMLSchema#string

Shao-Zhang Zhou

http://www.w3.org/2001/XMLSchema#string

Zhong-Guo Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Practical methods for incorporating summary time-to-event data into meta-analysis

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

P304

1271-1278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2014.1576

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263295586

http://www.w3.org/2001/XMLSchema#string

P698

24940424

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3991506

http://www.w3.org/2001/XMLSchema#string